[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100112905":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":22,"centralContacts":27,"locations":28,"responsibleParty":40,"collaborators":27,"id":42,"slug":43,"hasResults":44,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":27,"eligibilityCriteria":48,"healthyVolunteers":49,"sex":50,"minAge":51,"maxAge":52,"enrollmentInfo":53,"targetDuration":27,"studyType":56,"phases":57,"briefSummary":60,"conditions":61,"keywords":63,"overallStatus":65,"whyStopped":66,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":75},{"fullName":5,"class":6},"Phytotox SA","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"2","PLACEBO_COMPARATOR","Volunteers will be their own control by randomly receiving the active on one face side and the placebo on the opposite one.",[13],"Other: Wrinkle cream application",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"OTHER","Wrinkle cream application","Single application on the crow's feet wrinkles. Placebo cream will be applied on one side, the active cream on the other side.",[9],[21],"No other product will be used.",[23],{"name":24,"affiliation":25,"role":26},"Silvia H Pérez-Damonte, PhD","CLAIM","PRINCIPAL_INVESTIGATOR",null,[29],{"facility":25,"status":27,"city":30,"state":31,"zip":27,"country":32,"countryCode":33,"cosmosGeoPoint":34,"geoPoint":39,"contacts":27},"Buenos Aires","Buenos Aires F.D.","Argentina","AR",{"type":35,"coordinates":36},"Point",[37,38],-58.37723,-34.61315,{"lat":38,"lon":37},{"type":27,"investigatorFullName":27,"investigatorTitle":27,"investigatorAffiliation":27,"oldNameTitle":41,"oldOrganization":25},"Dra Silvia Pérez Damonte","100112905","phase-1-efficacy-and-safety-of-a-cutaneous-formulation-of-gonyautoxin-23-gtx-23-for-the-treatment-of-facial-wrinkles-100112905",false,"NCT00734786","Efficacy and Safety of a Cutaneous Formulation of Gonyautoxin 2\u002F3 (GTX 2\u002F3) for the Treatment of Facial Wrinkles","Efficacy and Safety of a Cutaneous Formulation of Gonyautoxin 2\u002F3 (GTX 2\u002F3) for the Treatment of Facial Wrinkles. Study # CLN 08-003.","Inclusion Criteria:\n\n* Women with no bearing-child potential or with adequate birth control method.\n* Volunteers between 30 to 60 years of age.\n* Subjects with bilateral crow's feet wrinkles.\n* Regular user of cosmetic products, willing and able to comply with the study objectives.\n* Signed informed consent.\n\nExclusion Criteria:\n\n* Any medical condition or any use of a medication that could modify the study results (e.g.: NSAIDs, immunosuppressant drugs, insulin...).\n* Any other significant medical condition (e.g.: diabetes mellitus, heart disease, liver disease...).\n* Any other condition that in the investigator's opinion could not be appropriate with the participation in this trial.\n* Any health condition that could affect the evaluation of study parameters.\n* Acute or chronic skin disease.\n* History of allergic reaction to cosmetic compounds.\n* Pregnancy, planned pregnancy or breast-feeding.\n* Allergy to shellfish, fish or sea product (seaweed).\n* Known or suspected hypersensitivity to any of the study product compounds.\n* Participation in another clinical trial within 30 days previous to enrolment.\n* Known or suspected alcohol or drug abuse.",true,"FEMALE","30 Years","60 Years",{"count":54,"type":55},15,"ESTIMATED","INTERVENTIONAL",[58,59],"PHASE1","PHASE2","The main objective of the trial is to determine whether the current topical formulation of GTX 2\u002F3 reduces the wrinkling of the skin (crow's feet) after a single application\n\nOther evaluation criteria include: safety assessment and local tolerance, depth of facial wrinkles (video microscopy imaging).",[62],"Facial Wrinkles",[64],"gonyautoxin","WITHDRAWN","Study cancelled.","2008-08-22",{"date":69,"type":55},"2008-08-25",{"date":71,"type":27},"2008-08",{"date":73,"type":55},"2008-09",{"name":5,"class":6},1]